Skip to content

Clinical trials

Observational Recurrence trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Recurrence Phase: Observational Clear all

494 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20005
20011
20023
20032
20045
20059
200610
200711
20088
200913
201016
20117
201211
201310
201421
201524
201621
201721
201828
201931
202044
202127
202239
202330
202431
202521
202629

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed225
Unknown status111
Recruiting70
Not yet recruiting29
Active, not recruiting21
Terminated21
Withdrawn9
Enrolling by invitation7
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Celgene7
Chang Gung Memorial Hospital7
Hospices Civils de Lyon7
Bristol-Myers Squibb6
National Taiwan University Hospital6
Samsung Medical Center5
Centre Hospitalier Universitaire de Saint Etienne4
Fudan University4
IRCCS Azienda Ospedaliero-Universitaria di Bologna4
Maastricht University Medical Center4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Recurrence494
Neoplasm Metastasis34
Neoplasms30
Multiple Myeloma23
Breast Neoplasms20
Carcinoma, Hepatocellular19
Leukemia, Myeloid, Acute18
Multiple Sclerosis18
Precursor Cell Lymphoblastic Leukemia-Lymphoma18
Lymphoma17

Trials

Showing 26 to 50 of 494. Each trial links to its page on Pharma Observatory.

394 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.